Aerie pharmaceuticals expects fy 2020 revenue between $100 million and $110 million

Aerie pharmaceuticals reports fourth quarter and full year 2019 financial results, provides 2020 guidance and business update.q4 adjusted loss per share $0.96.q4 gaap loss per share $1.21.q4 earnings per share estimate $-0.77 -- refinitiv ibes data.sees fy 2020 revenue $100 million to $110 million.entering 2020 with approximately $309 million of cash and investments.for 2020, we expect continued revenue growth while expenses remain consistent with 2019 levels.fy2020 revenue view $101.0 million -- refinitiv ibes data.
AERI Ratings Summary
AERI Quant Ranking